| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.12 | 0.4 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.13 | 0.4 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.13 | 0.4 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.054 | 0.4 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |